News

Find News

Filter articles

Showing 2671 to 2680 of 2888 results

Pfizer Australia faces antitrust accusations

Australia18-02-2014

Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.

Novartis boosts cancer immunotherapy research with CoStim acquisition

US18-02-2014Mergers & acquisitions

Novartis has announced it will acquire biotechnology company CoStim for an undisclosed sum.

Baker & McKenzie adds to IP team

UK17-02-2014

Baker & McKenzie LLP has added to its IP team with the appointment of Hiroshi Sheraton as partner in its London office.

MSF criticises US pressure on Indian patent policy

India, US17-02-2014

Humanitarian organisation Médecins Sans Frontières has criticised the US for pressuring the Indian government to review its patent policies.

Myriad and Gene by Gene settle BRCA litigation

US13-02-2014Legal developments

Myriad and its rival genetic diagnostics company Gene by Gene have agreed to settle their patent infringement case related to BRCA tests.

US Chamber of Commerce slams Indian patent practices

India, US12-02-2014

The US Chamber of Commerce has criticised India’s “recent pattern of pharma patent denials”, which it says “are not about access to medicine”.

Merck and Samsung Bioepis agree diabetes deal

South Korea, US11-02-2014

Pharmaceutical company Merck and Samsung Bioepis, a joint venture between South Korean firm Samsung and Biogen, have agreed to work on a diabetes treatment.

Appeals court ruling blocks Lyrica competition until 2018

US10-02-2014

The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.

Roche sues Mylan over Herceptin biosimilar

India07-02-2014Legal developments

Roche’s Indian subsidiary has sued Mylan and Bangalore-based pharmaceutical company Biocon at the Delhi High Court, for launching a biosimilar of its breast cancer drug Herceptin (trastuzumab).

Myriad Genetics to acquire diagnostic company Crescendo

US06-02-2014Mergers & acquisitions

Myriad Genetics has entered into a definitive agreement to acquire inflammatory and autoimmune diagnostics company Crescendo Bioscience for $270 million.

Showing 2671 to 2680 of 2888 results

LSIPR